- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02379988
Prone Breath Hold Technique to Decrease Cardiac and Pulmonary Doses in Women Receiving Left Breast Radiotherapy
April 24, 2023 updated by: University of Arizona
Pilot Study For Prone Breath Hold Technique to Decrease Cardiac and Pulmonary Doses in Women Receiving Left Breast Radiotherapy
This is a pilot study to determine whether the addition of inspiratory hold (breath holding) can decrease the radiation dose that the heart and lung receive for patients being treated for left sided breast cancer.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Subjects have a standard of care CT simulation, which includes an additional breath hold CT.
Inspiratory gated breath-hold will be used.
Two radiation plans will be generated: one for the CT scan performed free breathing, and one for the CT scan performed with inspiratory gated breath hold.
The cardiac and lung doses will be determined.
At the discretion of the treating physician, the plan with the lower cardiac and lung dose may be used to treat the patient.
Study Type
Interventional
Enrollment (Actual)
15
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85724-5024
- Radiation Oncology Department at the University of Arizona Heath Network
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients of Dr. Gonzalez
- ≥18 years of age
- Node-negative left breast cancer
- Invasive or DCIS breast cancer
- Prior lumpectomy
- Deemed appropriate for treatment in the prone position by the treating physician
- Able to tolerate prone position and breath hold during CT simulation
Exclusion Criteria:
- <18 years of age
- Patients requiring treatment in supine position
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Verify radiation dose to heart and lung
Subjects will undergo the standard of care CT simulation, which includes an additional breath hold CT.
Inspiratory gated breath-hold will be used.
Two radiation plans will be generated: one for the CT scan performed free breathing, and one for the CT scan performed with inspiratory gated breath hold.
The cardiac and lung doses will be determined.
At the discretion of the treating physician, the plan with the lower cardiac and lung dose may be used to treat the patient.
|
This is a pilot study to determine whether the addition of inspiratory hold (breath holding) can decrease the radiation dose that the heart and lung receives for patients being treated for left sided breast cancer.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Radiation Dose in Gy to the Heart and Lung Using Two Radiation Techniques.
Time Frame: Treatment Day 1 (both pFB and pDIBH scans were done on the same day)
|
The primary endpoints of this study were to evaluate the feasibility of the combination of prone positioning and RPM pDIPH for breast cancer radiation treatment.
Each woman enrolled in the study had 2 radiation plans generated: one for the pFB scan and one for the pDIBH scan.
The mean difference between the dosimetrically determined heart, left anterior descending (LAD) artery, and left lung radiation doses were computed with the associated 95% confidence interval; however, the Wilcoxin paired signed rank test was used and listed below as the primary analysis because of the non-normal distributions.
|
Treatment Day 1 (both pFB and pDIBH scans were done on the same day)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Determination of Cardiac Dose and Lung Dose Reduction in Women Receiving Prone Breast Radiotherapy When Inspiratory Gating is Added.
Time Frame: Treatment Day 1
|
This outcome was measured by looking at the maximum dose to the heart and maximum dose to the left lung in patients using the free breathing method versus the breath holding method in the prone position.
The mean of the maximum doses for each patient was taken and compared using the Wilcoxin Paired Signed Rank Test.
|
Treatment Day 1
|
|
Heart Mean Dose Based on Breast Volume
Time Frame: Treatment Day 1
|
The breast volume was evaluated using the dose-volume histogram.
A paired t-test was used to assess if breast volume and the mean difference for heart was statistically significant.
Because paired data were generated the number of women required was less than if 2 independent samples of women were to be used.
|
Treatment Day 1
|
|
Determination of Left Anterior Artery (LAD) Dose Reduction in Women Receiving Prone Breast Radiotherapy When Inspiratory Gating is Added.
Time Frame: Treatment Day 1
|
This outcome was measured by looking at the maximum dose to the LAD in patients using the free breathing method versus the breath holding method in the prone position.
The mean of the maximum doses for each patient was taken and compared using the Wilcoxin Paired Signed Rank Test.
|
Treatment Day 1
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Victor J Gonzalez, MD, University of Arizona Radiation Oncology
- Principal Investigator: Uma Goyal, MD, University of Arizona Radiation Oncology
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 6, 2014
Primary Completion (Actual)
July 3, 2016
Study Completion (Actual)
July 3, 2016
Study Registration Dates
First Submitted
January 26, 2015
First Submitted That Met QC Criteria
February 27, 2015
First Posted (Estimate)
March 5, 2015
Study Record Updates
Last Update Posted (Actual)
May 17, 2023
Last Update Submitted That Met QC Criteria
April 24, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- 1409500149
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
Clinical Trials on Verify radiation dose to heart and lung
-
Hospital Provincial de CastellonRecruitingPneumonia, Viral | COVIDSpain
-
University of ZurichRecruitingCovid19 | ARDSSwitzerland
-
Hospices Civils de LyonRecruitingAcute Respiratory Distress SyndromeFrance
-
Henan University of Traditional Chinese MedicineUnknownChronic Respiratory Failure
-
Kyung Hee University Hospital at GangdongUnknownAlzheimer DiseaseKorea, Republic of
-
The University of Texas Health Science Center at...Completed
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingPreterm Infant | Intrauterine Growth Retardation (IUGR) | Respiratory Monitoring | Lung Function TestsItaly
-
Dokuz Eylul UniversityUnknown
-
New York UniversityNational Institute of Mental Health (NIMH); Beth Israel Medical Center; St. Luke...CompletedHIV | Antiretroviral TherapyUnited States
-
St. Francis Hospital, New YorkUnknownCoronary Artery Disease | Platelet Aggregation Inhibitors | PCI- Percutaneous Coronary InterventionUnited States